ライフサイエンスコーパス: polycystic ovary

1 (anovulation with either hyperandrogenism or polycystic ovaries).

2 49 (21%) of the women had polycystic ovaries.

3 However, little is known about the cause of polycystic ovaries.

4 PR-4 females studied did not ovulate and had polycystic ovaries.

5 es and regular cycles and from 32 women with polycystic ovaries, 16 of whom had regular, ovulatory cy

6 idence of vascular dysfunction in women with polycystic ovaries and are compatible with the hypothesi

7 Polycystic ovaries and hyperandrogenemia are present in

8 eproductive function in women with epilepsy (polycystic ovaries and hyperandrogenemia), this was not

9 We related the prevalence of polycystic ovaries and the plasma concentrations of gona

10 ic ovarian syndrome, asymptomatic women with polycystic ovaries, and healthy controls.

11 Polycystic ovaries are a common disorder associated with

12 women with high ZAG had fewer MetS, IGT and polycystic ovaries as compared with the low ZAG PCOS wom

13 rinology clinics, 20 asymptomatic women with polycystic ovaries attending the family planning clinic,

14 owing 60 subjects: 20 symptomatic women with polycystic ovaries attending the reproductive endocrinol

15 ased density of small preantral follicles in polycystic ovaries could result from increased populatio

16 isease, ovarian primordial follicle loss and polycystic ovary disease were increased in F1 generation

17 emales, ovarian primordial follicle loss and polycystic ovary disease were increased in F3 generation

18 Thin women with polycystic ovaries have altered hypothalamic control of

19 Obese, hirsute women with polycystic ovaries have higher than normal ovarian secre

20 of female infertility and is associated with polycystic ovaries, hirsutism, obesity, and insulin resi

21 tages, was six-fold greater in biopsies from polycystic ovaries in anovulatory women than in normal o

22 ausible explanation for the pathogenesis of "polycystic" ovaries in hyperandrogenism.

23 nosed after irregular menses, hirsutism, and polycystic ovaries, is concerned about weight gain despi

24 elopment of dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health

25 Polycystic ovary syndrome (PCOS) affects 5% of reproduct

26 tatic model assessment [HOMA]) in women with polycystic ovary syndrome (PCOS) and chronic periodontit

27 terleukin-6 (IL-6) in non-obese females with polycystic ovary syndrome (PCOS) and either clinically h

28 tor of MMP-1 (TIMP)-1 ratio in patients with polycystic ovary syndrome (PCOS) and systemically health

29 Pregnant women with polycystic ovary syndrome (PCOS) are often overweight or

30 Ms R, a 27-year-old woman with polycystic ovary syndrome (PCOS) diagnosed after irregul

31 Women with polycystic ovary syndrome (PCOS) exhibit elevated androg

32 ars, it has been clearly documented that the polycystic ovary syndrome (PCOS) has major metabolic seq

33 female first-degree relatives of women with polycystic ovary syndrome (PCOS) have hyperandrogenemia

34 Approximately 70% of women with polycystic ovary syndrome (PCOS) have intrinsic insulin

35 an morphologic measurements for diagnosis of polycystic ovary syndrome (PCOS) in adolescents.

36 Polycystic ovary syndrome (PCOS) is a common endocrine d

37 Polycystic ovary syndrome (PCOS) is a common endocrine d

38 Polycystic ovary syndrome (PCOS) is a common problem amo

39 Polycystic ovary syndrome (PCOS) is a common, highly her

40 Polycystic ovary syndrome (PCOS) is a complex hormonal d

41 Polycystic ovary syndrome (PCOS) is a leading cause of a

42 The polycystic ovary syndrome (PCOS) is an extremely common

43 Polycystic ovary syndrome (PCOS) is associated with card

44 Polycystic ovary syndrome (PCOS) is associated with insu

45 Polycystic ovary syndrome (PCOS) is associated with the

46 Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingl

47 Polycystic ovary syndrome (PCOS) is frequently associate

48 nostic criteria in women suspected of having polycystic ovary syndrome (PCOS) is incomplete.

49 Polycystic ovary syndrome (PCOS) is the most common repr

50 ly, some studies have revealed the effect of polycystic ovary syndrome (PCOS) on gingival inflammatio

51 Polycystic ovary syndrome (PCOS) recently has been ident

52 Insulin resistance in polycystic ovary syndrome (PCOS) results from a postbind

53 hyperandrogenic insulin-resistant women with polycystic ovary syndrome (PCOS) who are at increased ri

54 d androgen excess with insulin resistance in polycystic ovary syndrome (PCOS) women.

55 Using an ovine model of polycystic ovary syndrome (PCOS), (pregnant ewes injecte

56 Maternal polycystic ovary syndrome (PCOS), a common metabolic dis

57 This would suggest that maternal polycystic ovary syndrome (PCOS), a condition associated

58 n to this model because it is usually due to polycystic ovary syndrome (PCOS), a condition in which i

59 nd stroma are also prominent features of the polycystic ovary syndrome (PCOS), a leading cause of inf

60 Endothelin-1 is elevated in women with polycystic ovary syndrome (PCOS), and may play a role in

61 alleles are associated with type 2 diabetes, polycystic ovary syndrome (PCOS), and size at birth.

62 Dyslipidemia is a feature of polycystic ovary syndrome (PCOS), but its pathogenesis r

63 Polycystic ovary syndrome (PCOS), characterized by incre

64 ty, and hirsutism, common characteristics of polycystic ovary syndrome (PCOS), improve with even mode

65 oxidative stress, in the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocr

66 thesis and/or metabolism in the aetiology of polycystic ovary syndrome (PCOS).

67 levels correlate with increased severity of polycystic ovary syndrome (PCOS).

68 yperandrogenism are the cardinal features of polycystic ovary syndrome (PCOS).

69 s increasing evidence of their importance in polycystic ovary syndrome (PCOS).

70 ciated with insulin resistance in women with polycystic ovary syndrome (PCOS).

71 fertility and thus serve as a model of human polycystic ovary syndrome (PCOS).

72 has metabolic advantages in the treatment of polycystic ovary syndrome (PCOS).

73 to the concentrations that can occur during polycystic ovary syndrome (PCOS).

74 An association between polycystic ovary syndrome (PCOS)and endometrial carcinom

75 d androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2).

76 ppearing more frequently in type 2 diabetic, polycystic ovary syndrome and CHD cases.

77 Obese women with the polycystic ovary syndrome are relatively unresponsive to

78 ene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretio

79 s for the analysis of a previously described polycystic ovary syndrome gene expression dataset.

80 MI 33 kg/m(2)), insulin-resistant women with polycystic ovary syndrome had aberrant skeletal muscle m

81 The two common forms of polycystic ovary syndrome have different origins in intr

82 Women with the polycystic ovary syndrome have insulin resistance and hy

83 of underlying androgen excess, particularly polycystic ovary syndrome in women.

84 The polycystic ovary syndrome is a common cause of infertili

85 Polycystic ovary syndrome is characterized by an excess

86 Polycystic ovary syndrome is estimated to affect 5-10% o

87 nce thought to affect primarily adult women, polycystic ovary syndrome is frequently diagnosed during

88 Polycystic ovary syndrome is the most common cause of an

89 the University of California, San Francisco, Polycystic Ovary Syndrome Multidisciplinary Clinic over

90 ndomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate

91 nificant benefit when including metformin in polycystic ovary syndrome treatment regimens.

92 evels, that they hypothesized could point to polycystic ovary syndrome underpinning these association

93 The polycystic ovary syndrome was defined according to modif

94 proate, is associated with the occurrence of polycystic ovary syndrome when used in young adulthood o

95 ons, linking dementia with bone development, polycystic ovary syndrome with cardiovascular developmen

96 Polycystic ovary syndrome, a fertility disorder affectin

97 eving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a

98 veral phenotypes, including type 1 diabetes, polycystic ovary syndrome, and birth weight.

99 g obesity, type 2 diabetes, hepatitis C, and polycystic ovary syndrome, and is a primary feature of m

100 a) improves ovulatory function in women with polycystic ovary syndrome, and specific dietary fatty ac

101 line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, inc

102 In obese women with the polycystic ovary syndrome, decreasing serum insulin conc

103 56), after adjustment for education, parity, polycystic ovary syndrome, energy intake, and physical a

104 an overview of our current understanding of polycystic ovary syndrome, its epidemiology and natural

105 ively due to its associations with diabetes, polycystic ovary syndrome, obesity and birth size.

106 eted educational qualification, nulliparity, polycystic ovary syndrome, physical activity, and body m

107 rched PubMed using a string of variations of polycystic ovary syndrome, therapy/treatment, and adoles

108 s the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory f

109 ulin resistance is observed in patients with polycystic ovary syndrome, we hypothesized that TAC or S

110 associated with infertile conditions such as polycystic ovary syndrome.

111 ix to eight weeks in 44 obese women with the polycystic ovary syndrome.

112 ostic decisions and treating infertility and polycystic ovary syndrome.

113 daily for 35 days in 61 obese women with the polycystic ovary syndrome.

114 genaemia which is a common characteristic of polycystic ovary syndrome.

115 ur to eight weeks in 24 obese women with the polycystic ovary syndrome.

116 0c17 alpha activity are both features of the polycystic ovary syndrome.

117 ulation rates among infertile women with the polycystic ovary syndrome.

118 seen in diseases of excess androgens such as polycystic ovary syndrome.

119 lays a key role in the early pathogenesis of polycystic ovary syndrome.

120 ND1A) previously shown to be associated with polycystic ovary syndrome.

121 of adolescents are presenting with signs of polycystic ovary syndrome.

122 enital adrenal hyperplasia often develop the polycystic ovary syndrome.

123 narche and hyperandrogenic disorders such as polycystic ovary syndrome.

124 serum androgen concentrations in women with polycystic ovary syndrome.

125 y in symptomatic and asymptomatic women with polycystic ovaries than in the controls (10.7, 14.1, and

126 In both ovulatory and anovulatory women with polycystic ovaries, we noted a significant increase in t

127 n disease (primary ovarian insufficiency and polycystic ovaries) were increased in the F3 generation